Special Issue

Skin Fibrosis and Cutaneous Wound Healing—2nd Edition

Message from the Guest Editor

During the wound healing process, epithelialization is completed and remodeling of the extracellular matrix that makes up the granulation tissue occurs. Fibroblasts and leukocytes disappear from the granulation tissue formed during the proliferative phase, and collagen fibers are altered to form scar tissue. Granulation tissue contains large amounts of type III collagen, which diminishes during maturation and is replaced by type I collagen. Collagen polymerizes through cross-linking, increasing the support and tensile strength of the scar. If inflammation is prolonged during this period, fibroblasts do not decrease and collagen production continues, causing hypertrophic scars and keloids. The purpose of this Special Issue is to focus on inflammation and fibrosis and to explore their mechanisms.

Guest Editor

Dr. Noriko Aramaki-Hattori

Department of Plastic and Reconstructive Surgery, Keio University Hospital, Tokyo 160-8582, Japan

Deadline for manuscript submissions

30 September 2025

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/218702

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).